Application of curcumin and afatinib for combined treatment of non-small cell lung cancer

Abstract

The invention relates to the field of medicines, particularly relates to an application of curcumin and afatinib as well as a pharmaceutically acceptable salt thereof for combined treatment of non-small cell lung cancer, and more particularly relates to the application for combined treatment of non-small cell lung cancer having drug resistance for gefitinib and erlotinib.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the use of curcumin, afatinib and pharmaceutically acceptable salts thereof in combined treatment of non-small cell lung cancer. Background technique [0002] Lung cancer is a disease that results from the uncontrolled growth of cells in the lung tissue. Over the past half century, the incidence and mortality of lung cancer have increased year by year, and it has developed from a rare disease in the early 20th century to the number one cancer killer in the world today. According to the data regularly published by the World Health Organization (WHO), the morbidity and mortality of lung cancer are on the rise in countries all over the world, especially in developed countries. It has become the most common tumor in many developed countries, ranking first among male malignant tumors. It is the second most common malignant tumor in women and women, and it is the most common cause of death amo...

AI Technical Summary

Problems solved by technology

However, there is no report on the combination of curcumin and tyrosine kinase

Images